Essential RA-ILD Risk Factors: Importance of Early Screening for Better Outcomes

Key Risk Factors for Rheumatoid Arthritis–Associated Interstitial Lung Disease (RA-ILD)

Patients at risk of developing RA-ILD often have certain factors, including:

• Male gender
• Older age
• History of smoking
• Pulmonary complications
• Presence of rheumatoid nodules
• Older age at RA onset
• Use of leflunomide (LEF)

Symptom Presentation and Diagnosis

Many patients with RA-ILD are asymptomatic or show nonspecific symptoms, such as cough or shortness of breath, in early stages. High-resolution CT scans may miss cases if only symptomatic patients are screened. Early detection is crucial for improving diagnosis and treatment outcomes.

Research Overview

Researchers conducted a systematic review and meta-analysis using databases like PubMed, Web of Science, and Scopus. They focused on cohort or case-control studies published by March 2021 that reported odds ratios (ORs) or hazard ratios (HRs) for RA-ILD risk factors. They excluded studies where patients had ILD before a diagnosis of RA.

Study Findings

The review identified 3075 studies, with 12 meeting the criteria for analysis. This included 3 case-control and 9 cohort studies, mostly from the US and published in the last five years. Sample sizes ranged from 210 to 30,512 patients, and RA-ILD incidence rates varied from 1.8 to 6.7 per 1000 person-years.

Identified Risk Factors

Seventeen risk factors for RA-ILD were identified, including:

• Treatment regimens (e.g., glucocorticoids, methotrexate, LEF, biologics)
• Demographic factors (gender, age, age at RA onset, smoking history)
• Comorbidities (pulmonary and systemic)
• Disease involvement (joint erosion, rheumatoid nodules)
• Disease Activity Score 28 (DAS28)
• Laboratory tests (rheumatoid factor, anticitrullinated peptide antibody, C-reactive protein, erythrocyte sedimentation rate)

Significant Associations

The study noted several significant associations:

• Male gender (relative risk [RR], 1.94; 95% CI, 1.33-2.85; P = .02)
• Older age at RA onset (RR, 1.05; 95% CI, 1.01-1.10; P = .02)
• Pulmonary comorbidities (RR, 2.72; 95% CI, 1.24-5.95; P = .01)
• Ever-smoker status (RR, 1.37; 95% CI, 1.09-1.71; P = .006)
• Presence of rheumatoid nodules (RR, 1.85; 95% CI, 1.36-2.51; P = .04)

Conclusion and Future Recommendations

The researchers acknowledged limitations in their study, noting that only a limited number of cohort and case-control studies were included. Despite this, they emphasized the need for early screening for ILD in high-risk patients. Early diagnosis and treatment can greatly improve patient outcomes, as pulmonary fibrosis is often irreversible.

“Given that pulmonary fibrosis is usually irreversible, it is crucial to screen for ILD in high-risk patients to achieve early diagnosis and treatment, leading to a better long-term prognosis.”

References

1. Yu C, Zhang Y, Jin S, et al. Risk factors for incidence of interstitial lung disease in patients with rheumatoid arthritis: a systematic review and meta-analysis. BMJ Open Respir Res. 2024;11(1):e001817. doi:10.1136/bmjresp-2023-001817
2. Dai Y, Wang W, Yu Y, Hu S. Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management. Clin Rheumatol. 2021;40(4):1211-1220. doi:10.1007/s10067-020-05320-z